Nanomaterials targeting ferroptosis for osteoarthritis treatment: a systematic review of preclinical evidence
Abstract
Background: Osteoarthritis (OA) lacks effective disease-modifying therapies. Ferroptosis, an iron-dependent form of programmed cell death, has emerged as a novel pathogenic mechanism in OA. Nanomaterials (NMs), with tunable physicochemical properties and targeting capacity, offer promising opportunities for ferroptosis modulation. This systematic review synthesizes preclinical evidence on NM-based strategies in OA.
Methods: This review followed PRISMA 2020 guidelines and was prospectively registered on INPLASY (INPLASY202570110). Comprehensive searches of seven databases (PubMed, Embase, Web of Science, Scopus, ProQuest, Ovid, Cochrane Library) were performed up to July 27, 2025. Eligible studies included in vitro and/or in vivo investigations of NM-based approaches targeting ferroptosis in OA models. Independent screening, data extraction, and risk of bias assessment were conducted. Owing to substantial heterogeneity in nanomaterial platforms, experimental models, and outcome measures, a qualitative evidence synthesis was performed and meta-analysis was not considered appropriate.
Results: Twenty-two eligible studies were identified. Investigated nanoplatforms included polymeric nanoparticles, metal-based carriers, nanozymes, hydrogels, and biomimetic systems. Across in vitro and in vivo models, NMs were reported to modulate ferroptosis through regulation of iron metabolism, scavenging of reactive oxygen species, reinforcement of antioxidant defenses, and modulation of…
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial
- Clinical Trial of Vadadustat in Patients with Anemia Secondary to Stage 3 or 4 Chronic Kidney Disease
- Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience
- Celecoxib or naproxen treatment does not benefit depressive symptoms in persons aged 70 and over: findings from a randomized controlled trial
- Comparative Clinical Effectiveness of Nonsurgical Treatment Methods in Patients With Lumbar Spinal Stenosis: A Randomized Clinical Trial
- Efficacy and safety of adalimumab by intra-articular injection for moderate to severe knee osteoarthritis: An open-label randomized controlled trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.